Healthcare Industry News: degenerative sacroiliitis
News Release - January 20, 2016
SI-BONE, Inc. Announces European Expansion with Formation of SI-BONE UK Ltd and Key Additions to Management TeamAppoints Richard Moss, General Manager, UK & Ireland and Silvio Tarantino, Finance Director, EMEA
SAN JOSE, Calif., Jan. 20, 2016 -- (Healthcare Sales & Marketing Network) -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced the expansion of its European operations with the formation of SI-BONE UK Ltd, along with the addition of two key management team members. Mr. Richard Moss joins the European management team as General Manager UK & Ireland and Mr. Silvio Tarantino has been appointed Finance Director for Europe, the Middle East and Africa (EMEA).
Mr. Moss will lead all operations of SI-BONE UK Ltd, which will be headquartered in Knaresborough, North Yorkshire, UK. The UK office will strengthen the company's presence in Europe by adding a third European office in addition to the existing EMEA headquarters in Gallarate, Italy and a second office in Mannheim, Germany that opened last year. Mr. Moss brings over 20 years of medical device sales experience from both multinational and start-up companies including ArthroCare, TranS1 and most recently, Aurora Spine. The addition of Mr. Moss and the UK office will provide a direct sales presence in the UK and Ireland and further strengthen SI-BONE's European sales organization.
Mr. Tarantino will manage all financial and business operations for Europe, the Middle East and Africa (EMEA) and will be located at the European headquarters in Gallarate, Italy. Mr.Tarantino began his career in the early 90's serving in various financial and general management roles in Bausch & Lomb and Smith & Nephew. From 1997 to 2001, he was Director of Finance at Modern Plastic Corporation based in New Jersey. From 2002 to 2008 he served as Integration Support Consultant for Recall Srl where he was responsible for the integration of four previously acquired companies and subsequently named General Manager of the Italian entity. We believe that Mr. Tarantino's strong financial management and business development experience with multinational organizations will support SI-BONE's expansion throughout the EMEA region.
"We are extremely excited to have both Richard and Silvio join our EMEA team and I look forward to working with both of them to further expand our presence in the UK and strengthen our overall business across Europe and the Middle East," said Andrea Mercanti, Vice President of EMEA at SI-BONE.
About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is a leading sacroiliac joint medical device company dedicated to the development of products for patients with low back issues related to certain SI joint disorders. The company develops, manufactures and markets minimally invasive products for patients with these disorders. SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.
The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, and allow for biological fixation to support long term fusion. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life at 12 months post-implantation. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks.
SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc.
©2016 SI-BONE, Inc. All Rights Reserved.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.